This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 2-8 July 2023 and includes updates on avian influenza in domestic cats, pride celebrations, diphtheria, COVID-19, West Nile virus, mass gatherings, measles, Middle East respiratory syndrome coronavirus (MERS-CoV), Mpox, and Ralstonia mannitolilytica in dialysis patients.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 11-17 June 2023 and includes updates on COVID-19, West Nile virus, chikungunya and dengue, avian influenza, measles, diphtheria, cholera, echovirus, and information on the Hajj.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 May 2023 and includes updates on COVID-19, influenza, Marburg virus disease, poliomyelitis, extensively drug-resistant Pseudomonas aeruginosa, and suspected fungal meningitis.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7-13 May 2023 and includes updates on measles, COVID-19, influenza and swine influenza, group A Streptococcal infection, Marburg virus disease, Lassa fever, diphtheria and mpox.
Between 2018 and 2020, nearly 20 000 surgical site infections (SSIs) were reported from a total of over 1.2 million surgical procedures in 13 EU/EEA countries participating in ECDC-coordinated SSI surveillance. Over 2 500 hospitals are part of this surveillance network.
This report is based on data for 2018-2020 retrieved on 13 February 2023 from The European Surveillance System (TESSy) and ECDC’s decentralised data storage for antimicrobial resistance and healthcare-associated infections (ARHAI). TESSy is a system for the collection, analysis and dissemination of data on communicable diseases.
This report presents the results of the first external quality assurance (EQA) scheme for B. pertussis antimicrobial susceptibility testing by ECDC as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) consortium.
This report presents the results of the first external quality assessment (EQA) scheme for Bordetella pertussis vaccine antigen expression, pertactin (PRN), pertussis toxin (PT) and filamentous haemagglutinin (FHA) by the European Centre for Disease Prevention and Control (ECDC) as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) activities.